BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
BMRN pays a steep premium—over 8x sales—for Amicus, aiming to diversify growth engines in rare diseases. The deal is expected to be accretive to 2027 earnings, but immediate gross leverage rises to 3.0–3.5x, with a target to deleverage below 2.5x in two years. Despite the premium and leverage, BMRN's shares surged, reflecting optimism about pipeline synergies but warranting caution after the valuation run-up. Catherine Delahaye/DigitalVision via Getty Images By the end of October, I concluded that BioMarin Pharmaceutical Inc. ( BMRN ) was showing growing numbers, yet it came with falling expectations. Shares had fallen to the lowest levels in a decade, despite profitable growth More on my IG service If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide cover
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- A $4.8 Billion Reason to Buy BioMarin Stock Today [Yahoo! Finance]Yahoo! Finance
- BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha]Seeking Alpha
- BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B [Yahoo! Finance]Yahoo! Finance
- BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- 12/17/25 - Form 8-K
- BMRN's page on the SEC website